T1	Participants 48 89	subjects with hepatitis C virus infection
T2	Participants 311 490	thrombocytopenic patients (n = 1463, age ≥ 18 years) with chronic HCV infection who were able to achieve a target platelet count of > 90 × 10(9) /L following eltrombopag treatment
